The viral vector market has seen significant advancements and growth in recent years. Viral vectors are a type of gene therapy tool that deliver genetic material into cells to treat or prevent diseases. The viral vector market includes various types of viral vectors, such as retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and lentiviral vectors.
Gene therapy is a rapidly growing field, and viral vectors are one of the most commonly used tools in gene therapy. With the increasing use of gene therapy to treat a range of diseases, including cancer, genetic disorders, and rare diseases, the demand for viral vectors is expected to continue to grow.
Scientists are constantly working on improving the design and production of viral vectors to make them safer and more effective. This includes modifying the viral vectors to target specific cells or tissues, improving their ability to deliver genetic material, and reducing their toxicity.
In addition to the traditional viral vector platforms, new vector platforms such as non-viral vectors, mRNA vaccines and gene editing tools like CRISPR-Cas9 are emerging, offering new opportunities to treat diseases. The growing demand for viral vectors has led to an increase in investment in companies that specialize in viral vector production and development. Several new companies have emerged in recent years, with significant investment from venture capital firms and pharmaceutical companies. Regulatory agencies such as the US FDA and the EMA have put in place frameworks to facilitate the development and approval of viral vectors, supporting innovation in this field. The first gene therapy products are now being commercialized, with a number of gene therapies receiving regulatory approval, opening up a new era of personalized medicine using viral vectors as a delivery mechanism.
Adeno-associated virus (AAV) vectors are currently the most widely used vectors in gene therapy. However, they have limitations such as limited cargo capacity and neutralizing antibodies that can affect their efficacy. Next-generation AAV vectors are being developed to overcome these limitations. These vectors have improved tropism, reduced immunogenicity, and increased cargo capacity, making them more efficient in delivering genes.
Lentiviral vectors are being used in chimeric antigen receptor (CAR)-T cell therapy to improve the efficacy and safety of this treatment. These vectors are used to engineer T cells to express CARs that can recognize and kill cancer cells. Overall, the viral vector market is expected to continue to grow as gene therapy becomes more widely used and as new vector platforms and improved production methods become available.
The market is segmented based on type, application, end-user, and region. The type segment is divided into Adeno-associated Virus (AAV), Lentivirus, Adenovirus, Retrovirus, Others. The application segment is divided into Cell & Gene Therapy, Vaccine, Biopharmaceutical & Pharmaceutical Discovery, and Biomedical Research. The end user segment is divided into Pharmaceutical & Biopharmaceutical Companies, Research Institutes, and Hospitals.
Viral Vector Market Key Players:
Viral Vector Market Segmentations:
By Type
By Application
By End user
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Type Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Viral Vector Market
5.1. COVID-19 Landscape: Viral Vector Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Viral Vector Market, By Type
8.1. Viral Vector Market, by Type, 2023-2032
8.1.1 Adeno-associated Virus (AAV)
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Lentivirus
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Adenovirus
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Retrovirus
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Viral Vector Market, By Application
9.1. Viral Vector Market, by Application, 2023-2032
9.1.1. Cell & Gene Therapy
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Vaccine
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Biopharmaceutical & Pharmaceutical Discovery
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Biomedical Research
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Viral Vector Market, By End user
10.1. Viral Vector Market, by End user, 2023-2032
10.1.1. Pharmaceutical and Biotechnology Companies
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Academic and Research Institute
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. CROs & CMOs
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Viral Vector Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2020-2032)
11.1.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.3. Market Revenue and Forecast, by End user (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.4.3. Market Revenue and Forecast, by End user (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.5.3. Market Revenue and Forecast, by End user (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2020-2032)
11.2.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.3. Market Revenue and Forecast, by End user (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.4.3. Market Revenue and Forecast, by End user (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.5.3. Market Revenue and Forecast, by End user (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.6.3. Market Revenue and Forecast, by End user (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.7.3. Market Revenue and Forecast, by End user (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2020-2032)
11.3.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.3. Market Revenue and Forecast, by End user (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.4.3. Market Revenue and Forecast, by End user (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.5.3. Market Revenue and Forecast, by End user (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.6.3. Market Revenue and Forecast, by End user (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.7.3. Market Revenue and Forecast, by End user (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.3. Market Revenue and Forecast, by End user (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.4.3. Market Revenue and Forecast, by End user (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.5.3. Market Revenue and Forecast, by End user (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.6.3. Market Revenue and Forecast, by End user (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.7.3. Market Revenue and Forecast, by End user (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.3. Market Revenue and Forecast, by End user (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.4.3. Market Revenue and Forecast, by End user (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.5.3. Market Revenue and Forecast, by End user (2020-2032)
Chapter 12. Company Profiles
12.1. Creative Biogene
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Vibalogics GmbH
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Takara Bio.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Cell and Gene Therapy Catapult
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. BlueBird Bio
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Addgene, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Aldevron, L.L.C.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Audentes Therapeutics.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. BioMarin Pharmaceutical
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. RegenxBio, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers